Summary
Amgen Inc. reported solid financial results for the third quarter and first nine months of 2022, demonstrating resilience despite a challenging macroeconomic environment. Total revenues for the nine months increased by 2% year-over-year to $19.48 billion, driven by product sales growth and increased other revenues. Net income also saw a significant increase of 24% for the same period, reaching $4.94 billion, with diluted Earnings Per Share (EPS) rising to $9.11. The company's operating income showed substantial growth, up 38% for the nine-month period, reflecting effective cost management and operational efficiency. The company continued its strategic capital allocation through robust share repurchases and dividend payments, underscoring its commitment to returning value to shareholders. Amgen also made significant progress on its pipeline, highlighted by positive trial results for LUMAKRAS/LUMYKRAS. The recent acquisition of ChemoCentryx, Inc. for approximately $3.7 billion is expected to further enhance its therapeutic offerings in autoimmune diseases, inflammatory disorders, and cancer, positioning the company for future growth.
Financial Highlights
54 data points| Revenue | $6.65B |
| Cost of Revenue | $1.59B |
| Gross Profit | $5.06B |
| SG&A Expenses | $1.29B |
| Operating Expenses | $3.99B |
| Operating Income | $2.66B |
| Interest Expense | $368.00M |
| Net Income | $2.14B |
| EPS (Basic) | $4.01 |
| EPS (Diluted) | $3.98 |
| Shares Outstanding (Basic) | 535.00M |
| Shares Outstanding (Diluted) | 538.00M |
Key Highlights
- 1Total revenues for the nine months ended September 30, 2022, increased by 2% to $19.48 billion compared to $19.13 billion in the prior year.
- 2Net income for the nine months increased by 24% to $4.94 billion, with diluted EPS rising to $9.11 from $6.93 in the prior year.
- 3Operating income saw a substantial increase of 38% for the nine months, reaching $7.34 billion.
- 4The company repurchased $6.3 billion of common stock during the first nine months of 2022, demonstrating a strong commitment to capital return.
- 5Amgen completed the acquisition of ChemoCentryx, Inc. on October 20, 2022, for approximately $3.7 billion, expanding its portfolio in autoimmune diseases and inflammation.
- 6Positive Phase 3 results for LUMAKRAS/LUMYKRAS in non-small cell lung cancer were announced, showing superior progression-free survival and response rates compared to chemotherapy.
- 7The company maintained compliance with its financial covenants, indicating a stable financial position.